Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999972 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01999972 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 50 participants.
The verdict
NCT01999972, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually develop evasive resistance. It is proposed that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor (HGF or scatter factor) contribute to VEGF inhibitor resistance, such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in combination with the VEGF inhibitor, axitinib.Since this will be the first study of axitinib given in combination with crizotinib, the study will primarily assess the safety and tolerability of the combination regimen.
Interventions
- DRUG axitinib
- DRUG crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-02-26 |
| Est. Completion | 2019-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999972
The ClinicalTrials.gov registry entry for NCT01999972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which axitinib is the first listed.
NCT01999972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999972 about?
NCT01999972 is a clinical study titled "A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors". Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually develop evasive resistance. It is proposed that mesenchymal-epithelial...
What is the current status of trial NCT01999972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2014-02-26. Estimated completion is 2019-09-05.
What interventions are being tested in trial NCT01999972?
The interventions under investigation include: axitinib (DRUG), crizotinib (DRUG).
Who is sponsoring clinical trial NCT01999972?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.